Nattokinase

PreclinicalProtein / enzyme

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Nattokinase is one of 51 small molecule programs targeting Cognitive Function. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive FunctionUnknown status

Efficacy and SafetyCompleted

Cognitive FunctionPreclinical

Unknown status

Efficacy and SafetyPreclinical

Completed

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

4 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 3

Rapamune

PPrism Pharmaceuticals

Phase 3

5 4

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 5

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 6

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 7

Becotatug Vedotin

FFudan University

Phase 3

1 8

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

1 9

VAY736

Novartis

Phase 3

2 10

Raphamin

MMateria Medica Holding

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cognitive Function1 trial

Improving Cerebral Blood Flow and Cognitive Function in Patients With Asymptomatic Intracranial / Carotid Stenosis With Nattokinase (ICC-PACS)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05200234·100 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Geneferm Nattokinase

Completed·—·N/A·NCT00749801·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Nattokinase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nattokinase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nattokinase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Nattokinase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cognitive Function1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News